Age-related tyrosine-specific protein phosphorylation defect in human T lymphocytes activated through CD3, CD4, CD8 or the IL-2 receptor.
Although transmembrane signaling defect has been recognized as one of the major functional alterations involved in immune senescence, its biochemical nature as well as its precise molecular localization are still unknown. The available data indicate that an early step in the signaling cascade may be affected during the aging process. Because protein tyrosine kinases (PTK) are ubiquitously implicated in the initiation of physiological signals, they appear as prime candidates for age-related changes. The present investigation examined the effect of age on the activity of PTK associated with CD3, CD4, CD8 or the IL-2 receptor (IL-2R) in human T lymphocytes. By comparison with cells derived from young individuals, anti-CD3-activated T lymphocytes from elderly donors were more susceptible to herbimycin A, a PTK inhibitor known to prevent signal transduction by the T cell antigen receptor. This increased sensitivity of cells from senescent organisms to PTK inhibitors is most likely related to a lesser PTK activity since a significant decrease in the tyrosine phosphorylation of particular endogenous substrates was observed as a consequence of either CD3, CD4, CD8 or IL-2R activation. However, no age-related difference in tyrosine phosphorylation could be demonstrated when T cells were activated by pervanadate, a pharmacological activator of PTK. These results suggest that the intrinsic activity of the enzymes is preserved and that the age-associated defect in PTK activation occurs as a consequence of an upstream biochemical alteration. The defect in PTK activation could be the primary cause for the dysfunction of various components of the signaling cascade observed during the course of aging.
Quadri
R A
RA
Department of Geriatrics, University of Geneva, Switzerland.
Plastre
O
O
Phelouzat
M A
MA
Arbogast
A
A
Proust
J J
JJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000097:blood* / Q000276:immunology; D015703:Antigens, CD / Q000097:blood*; D016227:Benzoquinones; D001782:Blood Donors; D017252:CD3 Complex / Q000097:blood; D015704:CD4 Antigens / Q000097:blood; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D047029:Lactams, Macrocyclic; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000097:blood*; D011809:Quinones / Q000494:pharmacology; D015375:Receptors, Interleukin-2 / Q000097:blood*; D017828:Rifabutin / Q000031:analogs & derivatives; D013601:T-Lymphocytes / Q000276:immunology*; D014638:Vanadates / Q000494:pharmacology
D015703:Antigens, CD; D016227:Benzoquinones; D017252:CD3 Complex; D015704:CD4 Antigens; D004791:Enzyme Inhibitors; D047029:Lactams, Macrocyclic; D011809:Quinones; D015375:Receptors, Interleukin-2; C076715:pervanadate; D017828:Rifabutin; D014638:Vanadates; C020754:herbimycin; D011505:Protein-Tyrosine Kinases